Post-operative avoidance of radiotherapy: biomarker selection of women categorised to be in a very low risk group by IHC4+C.
Disease site: Breast cancer
Treatment modality: Radiotherapy
Status: Open to recruitment
PRIMETIME is a phase III, multicentre trial which tests whether radiotherapy can be safely avoided in patients considered to have such a low risk of local recurrence that the potential absolute gain from radiotherapy does not outweigh the established risks associated with breast radiotherapy.
PRIMETIME will use immunohistochemical biomarkers with clinical information (IHC4+C) to direct selective avoidance of breast radiotherapy. The IHC4+C algorithm will be used to risk stratify patients into a very low risk group (recommended avoidance of radiotherapy) or not (standard radiotherapy).
Approximately 2,400 patients will be registered over four years to recruit 1,500 patients in the no radiotherapy group. All patients will be followed up for 10 years.
Chief Investigator: Dr Charlotte Coles, The University of Cambridge
ICR-CTSU Scientific Lead: Professor Judith Bliss
Trial management contact: [email protected]
Sponsor: The Institute of Cancer Research (ICR)
Funding: Cancer Research UK
View PRIMETIME on the National Institute for Health Research website: NIHR - Be Part Of Research and a plain English summary from Cancer Research UK.
PRIMETIME Study video
We have produced a video for patients who have been invited to take part in the PRIMETIME study. The video is supplemental to the PRIMETIME main study patient information sheets and decision aid diagrams provided to eligible patients by their study doctor or nurse. Please make sure that you have read the PRIMETIME main study patient information sheets and decision aid diagrams before you watch this video. The video is designed to build on the information you have already received from your doctor. Please contact your breast cancer team with any questions about the PRIMETIME study.
What the PRIMETIME video at www.icr.ac.uk/primetime
Publications and presentations
C.C. Kirwan, C.E. Coles, J. Bliss, On Behalf of the PRIMETIME Protocol Working Group; It's PRIMETIME. Postoperative Avoidance of Radiotherapy: Biomarker Selection of Women at Very Low Risk of Local Recurrence http://dx.doi.org/10.1016/j.clon.2016.06.007